Bristol Myers' transition moves forward as it raises 2025 revenue forecast

Max Gelman

Senior Editor

Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning.

While overall revenue declined by 6 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers' transition moves forward as it raises 2025 revenue forecast

Max Gelman

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche CEO warns that tariffs could impact dealmaking

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

Merck’s Gardasil sales sink further amid China market pressure

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Bris­tol My­er­s' tran­si­tion moves for­ward as it rais­es 2025 rev­enue fore­cast

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Bristol Myers' transition moves forward as it raises 2025 revenue forecast